Systematic and Quantitative Assessment of the Effect of Chronic Kidney Disease on CYP2D6 and CYP3A4/5

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2016 Jan 23

PMID 26800425

Citations 21

Authors

K Yoshida

B Sun

L Zhang

P Zhao

D R Abernethy

T D Nolin

A Rostami-Hodjegan

I Zineh

S-M Huang

Affiliations

Soon will be listed here.

Abstract

Recent reviews suggest that chronic kidney disease (CKD) can affect the pharmacokinetics of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways has not been systematically evaluated. In this study we developed a comprehensive dataset of the effect of CKD on the pharmacokinetics of CYP2D6- and CYP3A4/5-metabolized drugs. Drugs for evaluation were selected based on clinical drug-drug interaction (CYP3A4/5 and CYP2D6) and pharmacogenetic (CYP2D6) studies. Information from dedicated CKD studies was available for 13 and 18 of the CYP2D6 and CYP3A4/5 model drugs, respectively. Analysis of these data suggested that CYP2D6-mediated clearance is generally decreased in parallel with the severity of CKD. There was no apparent relationship between the severity of CKD and CYP3A4/5-mediated clearance. The observed elimination-route dependency in CKD effects between CYP2D6 and CYP3A4/5 may inform the need to conduct clinical CKD studies with nonrenally eliminated drugs for optimal use of drugs in patients with CKD.

Citing Articles

Advancing understanding of human variability through toxicokinetic modeling, in vitro-in vivo extrapolation, and new approach methodologies.

Kreutz A, Chang X, Hogberg H, Wetmore B Hum Genomics. 2024; 18(1):129.

PMID: 39574200 PMC: 11580331. DOI: 10.1186/s40246-024-00691-9.

Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin.

Kim B, Kim J, Lee S, Oh J, Cho J, Jang I CPT Pharmacometrics Syst Pharmacol. 2024; 14(2):246-256.

PMID: 39465597 PMC: 11812932. DOI: 10.1002/psp4.13263.

Inflammation Decreases Ciclosporin Metabolism in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

Malnoe D, Bories M, Pierre-Jean M, Marchand T, Le Corre P J Clin Pharmacol. 2024; 65(3):328-339.

PMID: 39382849 PMC: 11867918. DOI: 10.1002/jcph.6141.

Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach.

Tuloup V, Goutelle S, Tod M, Bourguignon L Clin Pharmacokinet. 2023; 62(2):307-319.

PMID: 36631686 DOI: 10.1007/s40262-022-01205-3.

Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease.

Fu C, Pei Q, Liang W, Yang B, Li W, Liu J Drug Des Devel Ther. 2022; 16:2261-2274.

PMID: 35860523 PMC: 9289454. DOI: 10.2147/DDDT.S362607.

References

Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N . The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet. 2004; 18(6):365-72. DOI: 10.2133/dmpk.18.365. View

Sayama H, Takubo H, Komura H, Kogayu M, Iwaki M . Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients. AAPS J. 2014; 16(5):1018-28. PMC: 4147047. DOI: 10.1208/s12248-014-9626-3. View

Tsujimoto M, Sugimoto S, Nagatomo M, Furukubo T, Izumi S, Yamakawa T . Possibility of decrease in CYP1A2 function in patients with end-stage renal disease. Ther Apher Dial. 2013; 18(2):174-80. DOI: 10.1111/1744-9987.12100. View

Roy M, Erdman K, Abeyratne A, Plumb L, Lasseter K, Riff D . Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment. Clin Pharmacokinet. 2013; 52(5):385-95. DOI: 10.1007/s40262-013-0047-8. View

Yeung C, Shen D, Thummel K, Himmelfarb J . Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2013; 85(3):522-8. PMC: 4276411. DOI: 10.1038/ki.2013.399. View

Nolin T, Frye R, Le P, Sadr H, Naud J, Leblond F . ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol. 2009; 20(10):2269-76. PMC: 2754095. DOI: 10.1681/ASN.2009010082. View

Suzuki Y, Fujioka T, Sato F, Matsumoto K, Muraya N, Tanaka R . CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease. Br J Clin Pharmacol. 2016; 80(6):1421-8. PMC: 4693498. DOI: 10.1111/bcp.12733. View

Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R . Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl). 1995; 122(3):223-9. DOI: 10.1007/BF02246543. View

Zhao P, de L T Vieira M, Grillo J, Song P, Wu T, Zheng J . Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012; 52(1 Suppl):91S-108S. DOI: 10.1177/0091270011415528. View

10.

Burgess E, Duff H, Wilkes P . Propafenone disposition in renal insufficiency and renal failure. J Clin Pharmacol. 1989; 29(2):112-3. DOI: 10.1002/j.1552-4604.1989.tb03296.x. View

11.

Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S . Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 1988; 33(5):996-1004. DOI: 10.1038/ki.1988.99. View

12.

Jordo L, Attman P, Aurell M, Johansson L, Johnsson G, Regardh C . Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet. 1980; 5(2):169-80. DOI: 10.2165/00003088-198005020-00004. View

13.

Weiner D . Public health consequences of chronic kidney disease. Clin Pharmacol Ther. 2009; 86(5):566-9. PMC: 2788514. DOI: 10.1038/clpt.2009.137. View

14.

Cerqueira P, Coelho E, Geleilete T, Goldman G, Lanchote V . Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. J Clin Pharmacol. 2005; 45(12):1422-33. DOI: 10.1177/0091270005281816. View

15.

Yamasaki K, Chuang V, Maruyama T, Otagiri M . Albumin-drug interaction and its clinical implication. Biochim Biophys Acta. 2013; 1830(12):5435-43. DOI: 10.1016/j.bbagen.2013.05.005. View

16.

Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A . Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011; 4(2):261-74. DOI: 10.1586/ecp.10.143. View

17.

Yeung C, Yoshida K, Kusama M, Zhang H, Ragueneau-Majlessi I, Argon S . Organ Impairment-Drug-Drug Interaction Database: A Tool for Evaluating the Impact of Renal or Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs. CPT Pharmacometrics Syst Pharmacol. 2015; 4(8):489-94. PMC: 4562165. DOI: 10.1002/psp4.55. View

18.

Jadhav P, Cook J, Sinha V, Zhao P, Rostami-Hodjegan A, Sahasrabudhe V . A proposal for scientific framework enabling specific population drug dosing recommendations. J Clin Pharmacol. 2015; 55(10):1073-8. DOI: 10.1002/jcph.579. View

19.

Degen J, Wolke E, Seiberling M, Pintar P, HOXTER G, Steinhauer H . [Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure]. Med Klin (Munich). 1993; 88(3):129-33, 171. View

20.

Nolin T, Naud J, Leblond F, Pichette V . Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008; 83(6):898-903. DOI: 10.1038/clpt.2008.59. View